Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

• New packaging line doubles Ritedose's capacity to package single, individually wrapped vial medications.
• The new Syntegon line will support Ritedose's ongoing manufacturing commitment for Verona Pharma's new COPD drug Ohtuvayre and some ophthalmic medications.

COLUMBIA, S.C., April 16, 2025 /PRNewswire/ -- Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) is adding a seventh Syntegon packaging line to its state-of-the-art manufacturing facility that will double the company's capacity.

Ritedose is the largest CDMO in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets. The new line will be operated by a team of highly skilled professionals committed to Ritedose's excellence in sterile manufacturing. 

The new Syntegon packaging system doubles Ritedose's capacity to deliver individually wrapped vial medications to patients. The packaging line will be able to process between 160 million and 170 million vials annually. By increasing efficiency and flexibility, Ritedose is poised to expand its packaging options to better serve the evolving needs of its customers.

The Syntegon Packaging line will support Ritedose's manufacturing efforts for Verona Pharma plc's Ohtuvayre, a new novel product for Chronic Obstructive Pulmonary Disease (COPD). Ohtuvayre, an innovative first-in-class PDE3 and PDE4 inhibitor, is the first inhaled product with a novel mechanism of action approved in more than 20 years. In September 2024, Ritedose announced it is the manufacturing partner of choice for Verona. In addition to Ohtuvayre, the additional packing line enables Ritedose to meet individually wrapped vial packaging needs for other disease states.

"At Ritedose, we make significant investments to support our expanding manufacturing efforts. This summer we expanded our sterile Blow-Fill-Seal (BFS) capabilities by an additional 180-million-unit dose capacity for ophthalmic and respiratory medications. These investments underscore our commitment to meeting the demands for high-quality, sterile unit dose solutions. Our seventh Syntegon packaging line will greatly enhance our ability to serve Verona Pharma and future clients," Ritedose President and Chief Executive Officer Jody Chastain said. 

For more than 20 years, Ritedose has relied on Syntegon Technology, a leader in processing and packaging, to deliver reliable, innovative solutions for its pharmaceutical products.

This latest addition—designed for automated secondary packaging of pharmaceutical and consumer goods—reinforces Ritedose's commitment to patient safety and quality. Created specifically for individually wrapped vial medications, the system maximizes output while drastically reducing waste.

Ritedose expects the packaging line to be in service by early summer of 2025. The automated system is currently undergoing Site Acceptance Testing at The Ritedose facility.

About The Ritedose Corporation 

Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company's process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. Ritedose: Passion and Precision with a Purpose. For more information visit Ritedose.com 

Media Contact:
Alex Keown
630-346-5141
[email protected]
On Behalf of Ritedose

SOURCE Ritedose